3-Hydroxybutyric Acid
In clinical developmentAlso known as Beta-Hydroxybutyrate, beta-Hydroxybutyric acid, 3-HYDROXY-BUTANOIC ACID.
Recent clinical, regulatory, research and industry developments relating to this drug.
The Influence of Ketogenic Diet on Gut Microbiota: Potential Benefits, Risks and Indications.
Impact of Recurrent Hypoglycemia on Brain Ketone Metabolism in Type 1 Diabetes
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade.
β-Hydroxybutyrate: A Signaling Metabolite.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes7
Journals, researchers & institutions
- Annual review of nutrition1
- Cancer research1
- JCI insight1
- Nutrients1
- Agostoni C1
- Alves Costa Silva C1
- Aprahamian F1
- Arnedos M1
- Asnicar F1
- Colomba E1
- Corsello A1
- Daillère R1
- Aix Marseille Université1
- Bambino Gesù Children Hospital1
- Boler-Parseghian Center for Rare and Neglected Diseases1
- Buck Institute for Research on Aging1
- CNRS and Université Orléans1
- Department of Clinical Sciences and Community Health1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as 3-Hydroxybutyric Acid in the shared literature.
Frequently co-studied with 3-Hydroxybutyric Acid in the research literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials